Microcap Ledger Whitehawk Therapeutics, Inc. $WHWK
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Morristown, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 57,009,010 [10-Q 2026-08-06]
What the company doesAI summary of filing
Whitehawk Therapeutics is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) for cancer treatment. The company licenses a portfolio of three next-generation ADC therapies from WuXi Biologics targeting PTK7, MUC16, and SEZ6 in various solid tumors including lung, ovarian, endometrial, and small cell lung cancers. Two candidates (HWK-007 and HWK-016) have initiated Phase 1 clinical trials with data expected in the first half of 2027, while a third candidate (HWK-206) is planned for IND submission in mid-2026. The company is pre-revenue from its ADC pipeline and recently divested its legacy FYARRO product to focus on developing these next-generation therapies using an outsourced virtual model. [10-K 2026-03-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $0.00 | −$38.83M | −$36.74M | $85.23M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $7.14M | −$20.60M | −$97.43M | $37.57M | [10-K 2026-03-12] |
| FY ended Dec 2024 | $25.98M | −$63.69M | −$59.55M | $28.67M | [10-K 2026-03-12] |
- Quarterly cash burn
- −$18.37M
- Cash runway Estimate
- ~13.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-01 | 24,647,392 | [10-Q 2024-11-06] |
| 2025-03-24 | 46,784,618 | [10-K 2025-03-28] |
| 2025-05-02 | 47,109,293 | [10-Q 2025-05-08] |
| 2025-08-04 | 47,128,362 | [10-Q 2025-08-07] |
| 2025-11-04 | 47,128,362 | [10-Q 2025-11-06] |
| 2026-03-09 | 47,196,564 | [10-K 2026-03-12] |
| 2026-05-04 | 49,452,463 | [10-Q 2026-05-07] |
| 2026-08-03 | 57,009,010 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-05-29; declared effective 2026-06-09 [S-3 2026-05-29]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-05-14 | Dalal Anupam | grant | 1,275,510 | $3.92 | [4 2026-07-30] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-10 | 8-K | Director or officer change |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-08-06 | 8-K | Results of operations |
| 2026-06-12 | 8-K | Shareholder vote results |
| 2026-05-29 | S-3 | Registration statement |
| 2026-05-21 | 8-K | Other events |
| 2026-05-18 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-05-07 | 10-Q | Quarterly report |
Alerts for $WHWK
Email me when Whitehawk Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.